

**SOHM, INC.**  
**FINANCIAL REPORT**  
**FOR THE QUARTER ENDED**  
**September 30, 2022**

## **Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**

### **SOHM, INC.**

A Nevada Corporation

4195 Chino Hills Parkway, Suite 675  
Chino Hills, CA 91709 USA

Ph: (714)-522-6700

www.sohm.com

info@sohm.com

SIC Code: 2834

### **Quarterly Report**

**For the Period Ending: 09/30/2022**  
(the "Reporting Period")

As of 09/30/2022, the number of shares outstanding of our Common Stock was:

1,575,576,407

As of 06/30/2022, the number of shares outstanding of our Common Stock was:

1,575,576,407

As of 12/31/2021, the number of shares outstanding of our Common Stock was:

1,575,576,407

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐

No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐

No: ☒

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

---

<sup>1</sup> "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

Yes: ☐ No: ☒

1) **Name of the issuer and its predecessors (if any)**

**SOHM, Inc. (the "Issuer" or the "Company") formerly Alpine TLI Group, Inc.**

The Issuer was organized under the corporate laws of the State of Nevada on July 6, 2005. The Issuer operated as a California C Corporation from January 1998, until it merged with Alpine TLI Group in August 2008 and changed its name to SOHM Inc. and its status is active.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The state of Nevada and the current status is active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

4195 Chino Hills Parkway, # 675, Chino Hills, CA 91709

The address(es) of the issuer's principal place of business:

*Check box if the principal executive office and principal place of business are the same address:* ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

N/A

2) **Security Information**

Trading symbol:	<u>SHMN</u>
Exact title and class of securities outstanding:	<u>COMMON STOCKS</u>
CUSIP:	<u>83408P 108</u>
Par or stated value:	<u>\$0.0001</u>

Total shares authorized: 2,000,000,000 as of date: 09/30/2022

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Total shares outstanding: 1,575,576,407 as of date: 09/30/2022  
Number of shares in the Public Float<sup>2</sup>: 1,257,081,890 as of date: 09/30/2022  
Total number of shareholders of record: 345 as of date: 09/30/2022

*Additional class of securities (if any):*

Trading symbol: SHMN  
Exact title and class of securities outstanding: PREFERRED STOCKS  
CUSIP: N/A  
Par or stated value: \$0.0001  
Total shares authorized: 100 as of date: 09/30/2022  
Total shares outstanding: 51 as of date: 09/30/2022

#### Transfer Agent

Pacific Stock Transfer Company  
6725 Via Austi Pkwy, Suite 300  
Las Vegas, Nevada 89119

Phone-702.361.3033

Fax- 702.433.1979

Toll Free – 800.785.PSTC(7782)

Is the Transfer Agent registered under the Exchange Act?<sup>3</sup> Yes: ☒ No: ☐

### 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Number of Shares outstanding as of <u>12/31/2020</u>	<u>Opening Balance:</u> Common: 1,575,576,407 Preferred: <u>51</u>		*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation,	Number of Shares	Class of Securities	Value of shares issued (\$/per	Were the shares issued at a discount to	Individual/ Entity Shares were	Reason for share issuance (e.g. for cash or debt conversion) OR	Restricted or Unrestricted	Exemption or

<sup>2</sup> "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

<sup>3</sup> To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

	shares returned to treasury)	Issued (or cancelled)		share) at Issuance	market price at the time of issuance? (Yes/No)	issued to (entities must have individual with voting / investment control disclosed).	Nature of Services Provided (if applicable)	as of this filing?	Registration Type?
06/10/2020	New Issuance	13,888,889	Common	0.00027	Yes	Stacey Jenkins	Legal Service	Restricted	N/A
Shares Outstanding on 09/30/2022 :	Ending Balance: Common: <u>1,575,576,407</u> Preferred: <u>51</u>								

**Example:** A company with a fiscal year end of December 31<sup>st</sup>, in addressing this item for its quarter ended September 30, 2018, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2016 through September 30, 2018 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

On July 1, 2016, Shailesh Shah retired his 107,604,173 common shares and on July 13, 2016, Shailesh Shah transferred all of his shares of Series A Preferred stock (51 shares).

1. On December 6, 2019 company has issued 13,888,889 restricted stocks to Stacey Jenkins Esq for the legal service rendered by him.
2. On June 10, 2020 company has issued 13,888,889 restricted stocks to Stacey Jenkins Esq for the legal service rendered by him.

## B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
02/06/2012	\$ 115,000	\$94250	\$20750	12/31/22 (Extendable)	Negotiable	Lotus Enterprises Ltd.  (Control Person: Jayanth Murthy)	Loan for expansion

<u>10/14/2010</u>	<u>\$772,000</u>	<u>\$772,000</u>	<u>\$0</u>	<u>04/30/23</u> <u>(Extendable)</u>	<u>Negotiable</u>	<u>Chanakya FZE Ltd.</u>  <u>(Control Person:</u> <u>Vinod Kataria</u>	<u>Loan for</u> <u>expansion</u>
<u>04/15/2014</u>	<u>\$25,000</u>	<u>\$25,000</u>	<u>\$0</u>	<u>12/31/22</u> <u>(Extendable)</u>	<u>Negotiable</u>	<u>Hitendra Saraiya</u>	<u>Loan for</u> <u>expansion</u>
<u>11/20/2013</u>	<u>\$141,000</u>	<u>\$141,000</u>	<u>\$0</u>	<u>12/31/22</u> <u>(Extendable)</u>	<u>Negotiable</u>	<u>Smita Parikh</u>	<u>Loan for</u> <u>expansions</u>
<u>12/13/2013</u>	<u>\$8,000</u>	<u>\$8,000</u>	<u>\$0</u>	<u>12/31/22</u> <u>(Extendable)</u>	<u>Negotiable</u>	<u>Snehal Shah</u>	<u>Loan for</u> <u>expansion</u>
<u>08/15/2015</u>	<u>\$46,000</u>	<u>\$46,000</u>	<u>\$0</u>	<u>12/31/22</u> <u>(Extendable)</u>	<u>Negotiable</u>	<u>Keith Bauer</u>	<u>Loan for working</u> <u>capital</u>
<u>04/15/2011</u>	<u>\$63,942</u>	<u>\$63,942</u>	<u>\$0</u>	<u>12/31/22</u> <u>(Extendable)</u>	<u>Negotiable</u>	<u>Swati Shah</u>	<u>Loan for</u> <u>expansion</u>

Use the space below to provide any additional details, including footnotes to the table above:

**Company doesn't have any convertible notes, debt arrangements or promissory notes during last 2 years**

#### 4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP  
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)<sup>4</sup>:

Name: **FRED SCHELLACK**  
Title: **ACCOUNTANT**  
Relationship to Issuer: **OUTSIDE ACCOUNTANT**

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;  
D. Statement of income;  
E. Statement of cash flows;  
F. Financial notes; and  
G. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

<sup>4</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below.

Please see financial statements at the end of this disclosure.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

## **5) Issuer's Business, Products, and Services**

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

### **Generic Pharmaceutical Manufacturer**

#### **Company Overview**

SOHM, Inc. (SHMN) is a pharmaceutical manufacturer that produces and markets generic drugs for all major treatment categories. In February 2009, the Company had obtained a direct manufacturing license under Current Good Manufacturing Practice (CGMP) and initiated processes to be compliant with World Health Organization (WHO) regulations to produce generic as well as OTC pharmaceuticals. This authorization process provides the Company with manufacturing competencies for a wide variety of products covering various therapeutic segments. SHMN has private label license agreements with two companies to produce pharmaceuticals and OTC products.

The Company's strategic manufacturing facility enables low production costs without compromising quality. SHMN develops, manufactures and markets generic pharmaceuticals in various dosage forms, including tablets and capsules, creams and topicals, ointments, liquids and injectables. At present, SHMN has global licenses to manufacture more than 15 products and approximately 300 generic drugs and product formulations for distribution.

SHMN markets and sells its generic drugs globally but focuses primarily on emerging markets in Africa, Latin America, Southeast Asia and the European Union. The Company's global headquarters is located in North America and it had offices in China, India and the U.K.

#### **Generic Drug Manufacturing Expertise**

SHMN's proprietary processes and formulation capability allow it to develop generic formulations of brand-names that don't infringe on valid patents relating to the brand-name product. Demand for generic pharmaceuticals is increasing as a result of increasing awareness and acceptance of generics by consumers, physicians and, pharmacists globally. In addition, government agencies and private managed care/ insurance programs encourage the substitution of generics for brand-name pharmaceuticals as a cost-savings measure. SHMN has developed the ability to bridge the gap between demand and supply for generic and OTC products cost-effectively with consistent quality deliverables.

#### **Infrastructure To Support Manufacturing and Export**

By consolidating its pharmaceutical assets in India, the Company has a generic drug manufacturing hub where it capitalizes on low prices, strong marketing, and global recognition of India's emerging role as a leading drug manufacturing center. In October 2008, SHMN obtained pharmaceutical drug licenses that enable it to sell in Africa, Latin America, and Southeast Asia. In February 2009, SHMN had obtained a direct manufacturing license for generic pharmaceuticals. This license completes the needed infrastructure development for its India manufacturing hub.

1. Issuer is a Nevada Corporation.
2. The Issuer operated as a California C Corporation from January 1998, until it merged with Alpine TLI Group in August 2008. The Issuer's predecessor was organized under the corporate laws of the State of Nevada on July 6, 2005.
3. The Issuer's fiscal year-end date is December 31.
4. The issuer and/or any predecessor has not, and is not, in the process of filing bankruptcy, receivership or any similar proceeding.
5. On August 25, 2008, SHMN entered into an agreement with Alpine TLI Group, Inc., the predecessor. The agreement was to acquire SHMN and pass control of the Company to the then current officers of SHMN being Swati Shah, President/CEO and Sharad Joshi, Secretary/Treasurer and CFO.
6. No default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the Issuer to make payments as of the most recent quarter and year end.
7. The Issuer changed control when it merged in September 2008.
8. The increases in outstanding equity securities have increased by more than 10%.
9. Below is a description of any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization

On August 26, 2008, the Board of Directors and majority shareholders of Alpine TLI Group, Inc. voted and confirmed the following:

- **Corporate Name Change, CUSIP Number Change and New Business Direction**

The stockholders and Board Members of Alpine TLI, Group voted to confirm the change of the name of the corporation to SOHM, Inc and also to apply for a new CUSIP number. The name change and CUSIP number change reflects the company's new business direction to directly supply dyes, chemicals, pigments, and supply steel wires to manufacturers for springs, automobiles and garment/textile industries through private label agreements.

- **Merger with SOHM Inc.**

The stockholders and Board Members voted to confirm the merger with SOHM, Inc.

- **Reverse Split**

The stockholders and Board Members voted to confirm a 50:1 reverse split.

- **CEO and Chairman Change**

The stockholders and board members voted to confirm a CEO and Chairman change effective September 5, 2008. Then current CEO and Chairman resigned, and Ms. Swati Shah assumed the position of President, CEO and Chairman of the Board and Mr. Sharad Joshi assumed the position of Secretary, Treasurer, CFO and Board Member. Mr. Sharad Joshi resigned as Secretary, Treasurer, CFO and Director effective March 31, 2009. Effective January 15, 2011 the stockholders & Board members voted to confirm a CEO & Chairman change. The then current CEO & Chairman Ms. Swati Shah resigned as President & CEO and took over as Vice President, Secretary & Director. Mr. Shailesh Shah assumed the position of President, CEO & Chairman of the Board. On August 31, 2015, Mr. Shailesh Shah resigned as President, CEO and Director. Swati Shah was appointed as President, CEO and Director and retained her



appointment as Secretary, Treasurer and CFO. On September 10, 2018, Swati Shah resigned as President, CEO and Director and Also as Secretary, Treasurer and CFO. Baron Night was appointed as President, CEO and Director and, appointed as Secretary, Treasurer and CFO.

10. Issuer's securities have not been de-listed and are not in the process of being de-listed by the Securities and Exchange Commission or the NASD.

11. There are no current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations.

#### **Business of Issuer**

1. The Primary SIC Code for the Issuer is 2834.
2. The Issuer is currently conducting operations.
3. The issuer is not and has not been a shell company.
4. There is no parent, or affiliate of the issuer.
5. The effect of the existing and probable new government regulations is that issuer is alert and watchful so as to be able to re-evaluate portions of its business plan.
6. No amount has been spent during each of the last two fiscal years on research and development activities, therefore no cost of such activities are borne directly by customers.
7. There are no known costs or effects of compliance with environmental laws, neither International, federal, state or local.
8. The Company currently has five, (5) full time employees.

#### **Investment Policies**

1. Investments in real estate or interest in real estate  
The Issuer does not intend to invest in Real Estate outside of ownership in its executive offices or manufacturing facilities.
2. Investments in real estate mortgages  
The Issuer does not intend to invest in any type of real estate mortgages.
3. Investments in Securities  
The Issuer does not intend to invest in short term or long-term securities

- B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

N/A

- C. Describe the issuers' principal products or services, and their markets

***Services Provided by SHMN, and their Markets***

SHMN develops and commercializes generic pharmaceuticals, utilizing its controlled-release and other in-house formulation technologies. The Company focuses on developing generic versions of brand-name products for which the patents are near expiration or expired and require proprietary formulation expertise. By innovating processes, and applied innovation, the Company's proprietary processes and formulation skills allow it to develop generic versions that replicate the brand-name products' physiological effects but don't infringe on any valid patents.

The Company actively reviews pharmaceutical patents and seeks opportunities to challenge patents it believes are either invalid or would not be infringed by a generic version. SHMN also enters into collaboration, alliances and partnerships to acquire rights to pharmaceuticals it does not own and to share development costs or resolve patent barriers to entry. Overall, the Company's generic product development strategy leverages a legal strategy predicated on non-infringement of established brand name pharmaceuticals and speed of filing and also provide applied innovation.

The Company has a manufacturing license of generic pharmaceuticals and currently produces and markets generic pharmaceutical products along with dermatology and Nutraceutical products. The classification and industry position allows for a significant increase in profit margins and scalability of manufacturing operations. This license provides SHMN the production infrastructure to operate as a corporate manufacturing hub located in India for the production and export of generic pharmaceuticals.

**CORPORATE OVERVIEW**

The Company's strategic manufacturing facility in an area is considered one of the safest and perfect for pharmaceutical operations. The facility is approximately 5,500 square feet. In February 2009, SHMN's manufacturing facility was licensed by the India FDA. The license indicates compliance with Current Good Manufacturing Practice (CGMP) Regulations: Division of Manufacturing and Product Quality and compliant with World Health Organization (WHO) regulations and FDA.

The manufacturing facility provides complete technical support for production activities and houses the following:

- A third-party quality control laboratory with instruments to provide, chemical and microbiological analytical support; to provide constant in-process checks
- A spacious raw materials storage area which provides separate storage facilities for incoming materials, quarantine materials, released materials, and a separate section for sampling under a controlled environment and isolated areas for dispensing of raw materials, through documented SOPs for stringent control systems of checks and balances.
- A finished goods warehouse for storage and distribution of finished goods.
- The company has signed a definitive agreement with one of the Southern California based pharmaceutical manufacturing facilities to acquire them.

**Corporate Strategy**

The Company produces premium-quality, affordable pharmaceuticals and meets the changing needs of the drug market with a continual flow of new products, broadening its product portfolio, optimizing a global supply chain, helping customers more efficiently manage their inventory and customizing distribution and shipping based on specific customer needs. SHMN plans to grow by extending its leadership position in emerging generic pharmaceutical markets in Africa, Latin America, Southeast Asia and other important international markets.

Key aspects of the Company's strategy include:

- Undertake applied innovation to find an optimum fit between demand and supply gaps in the generic industry.
- Increasing generic R&D capabilities, and applied formulations with the continuous incremental improvement which adds up to sustained innovative output, and greater production capacity;
- Establishing a high level of operational effectiveness oversight and quality control systems;
- Bridge the gap between demand and supply in cost-effective generics and branded generics; Providing high-quality products in markets that are currently underserved, poorly served, or under-subscribed by existing suppliers;
- Using cost-effective, up-to-date instruments and equipment and machineries; on an ongoing basis.
- Employing advanced electronic and information technology to reduce staffing and other operational costs; providing more system-based output with minimal human errors,
- Continuing to business scanning actively seek and evaluate potential mergers, acquisitions, collaborations and other business combinations; to enlarge capacities, competencies and innovations;
- Side stepping head-to-head competition with an established business in regions that already are well served and develop alternatives for unmet needs to enlarge innovative generics portfolio.

## **Sales and Marketing**

The Company's focus on a cluster of segments of customers who are drug wholesalers, mass merchandisers, warehousing chain drug stores, and mail-order pharmacies who have an extensive chain of retailers and loyal customer base, by doing so, SHMN does not need to re-invent its grass-root customers but rather SOHM markets its products both directly and through partner alliance agreements. SHMN focuses on fast-growing, underserved emerging markets in the Far East, Africa, newly added European Union states, and Latin America. Despite the challenges of the current economic climate, much of the world's population has a great need for basic pharmaceuticals, but these drugs are either too expensive or not available to vast populations in these regions. The Company recently expanded its generic drug distribution to address emerging pharmaceutical markets in Africa.

The Company's marketing effort focuses on:

- Identifying, through careful market research, un-served or underserved niche markets;
- Combining the core pharmaceutical business with ancillary marketing concepts, activities and operations;
- Identifying, negotiating, and entering into partnerships with larger, more established distributors;
- Utilizing advanced electronic and informational technologies in sales and marketing;

Accommodating special and ethical products when and where sufficient demand exists.

## **6) Issuer's Facilities**

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used, or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have

complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Issuer occupies approximately 1500 square feet of office space that is being leased by a company that is owned by the company's prior officer and director. The Issuer does not pay any rent for this space. The Issuer believes that the space is in good condition and properly insured. The major assets of the company comprise the following:

The Company is headquartered in Chino Hills, California, U.S.A. and the Company's strategic manufacturing facility is located in Southern California, in an area considered one of the safest and perfect for pharmaceutical operations. The facility is approximately 5,500 square feet.

Property of the issuer is in good condition. There are no limitations on the expansion capability of the Company.

## 7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>BARON NIGHT</u>	<u>SOLE OFFICER, DIRECTOR, CONTROL PERSON</u>	<u>4195 Chino Hills Parkway, #675, Chino Hills, CA 91709</u>	<u>10,000</u>	<u>Common</u>	<u>0.0006%</u>	<u>President and CEO</u>
<u>BHAT FAMILY TRUST</u> (Control person of trust Dr. Krishna Bhat)	<u>OWNER OF MORE THAN 5%</u>	<u>1302 Laurelview Drive, Johnstown, PA 15905</u>	<u>82,000,000</u>	<u>Common</u>	<u>5.20%</u>	<u>Shares acquired through investment in company</u>

## 8) Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

NO

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended, or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended, or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

NO

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

NO

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

NO

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NONE

## **9) Third Party Providers**

Please provide the name, address, telephone number and email address of each of the following outside providers:

### Securities Counsel

Name: CHASE CHANDLER  
Firm: BRUNSON CHANDLER & JONES, PLLC  
Address 1: 175 S. Main Street, Suite 1410  
Address 2: Salt Lake City, UT 84111  
Phone: (801) 303-5730  
Email: chase@bcjlaw.com

### Accountant or Auditor

Name: FRED SCHELLACK  
Firm: ACCOUNTING & MANAGEMENT SERVICES  
Address 1: 3239 West Tenaya Way  
Address 2: FRESNO, CA 93711  
Phone: 559-259-3468  
Email: schellack@sbcglobal.net

### Investor Relations Consultant

NONE

#### Other Service Providers

Provide the name of any other service provider(s), including, counsel, advisor(s) or consultant(s) **that assisted, advised, prepared or provided information with respect to this disclosure statement**, or provided assistance or services to the issuer during the reporting period.

NONE

#### **10) Issuer Certification**

##### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, BARON NIGHT certifies that:

1. I have reviewed this 3<sup>rd</sup> quarter of 2022 financial and disclosure statement of SOHM, INC.:
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, are fairly present in all material respects the financial condition, results of operations, and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated this 10<sup>th</sup> day of November 2022

**SOHM, INC.**

/s/ Baron Night

Baron Night, CEO & CFO

**SOHM, INC.**  
**FINANCIAL STATEMENT**  
**FOR THE QUARTER ENDED**  
**September 30, 2022**

**Item 1: Exact name of the issuer and the address of its principal executive offices.**

**Name of the Issuer:** SOHM, Inc.

**Principal Executive offices:** 4195 Chino Hills Parkway, # 675,  
Chino Hills, CA 91709

Telephone: (714) 522-6700  
Facsimile: (714) 523-4329  
Web site: [www.sohm.com](http://www.sohm.com)

**Investor Relation's Officer:** N/A

**Investor Relation's Office:** SOHM, Inc.  
4195 Chino Hills Parkway, # 675,  
Chino Hills, CA 91709

**Investor Relations' Telephone:** 714-522-6700  
**Investor Relations' Fax:** 714-523-4329  
**Investor Relations' Email:** [IR@sohm.com](mailto:IR@sohm.com)

**Item 2 Shares outstanding.**

The following table sets forth information concerning the equity securities of SOHM, Inc. as of September 30, 2022:

<b>SECURITIES AUTHORIZED AND OUTSTANDING Class</b>	<b>As of</b>	<b>Number of Shares Authorized</b>	<b>Number of Shares Outstanding</b>	<b>Number of shares in the Public Float</b>	<b>Total Number of Shareholders of Record</b>
Common	Sept. 30, 2022	2,000,000,000	1,575,576,407	1,257,081,890	344
Preferred	Sept. 30, 2022	100	51	0	1

**SOHM, INC.**  
**QUARTERLY REPORT**  
**FOR THE QUARTER ENDED SEP 30,2022**  
**BALANCE SHEET**  
**As of Sep 30, 2022**  
**(Unaudited)**

<b>PARTICULARS</b>	<b>QTR. 3RD - SEPT.30, 2022</b>	<b>YEAR TO DATE 2022</b>	<b>As on Dec 31 2021</b>
<b>CURRENT ASSETS</b>			
Cash and Bank Balance	6,299	6,299	6,819
Trade Receivables	13,100	13,100	11,110
Loans and Advances	0	0	0
Inventory	16,700	16,700	14,312
<b>Total Current Assets</b>	<b>36,099</b>	<b>36,099</b>	<b>32,241</b>
<b>EQUIPMENT, net</b>	<b>19,120</b>	<b>19,120</b>	<b>19,120</b>
<b>OTHER ASSETS</b>			
Subscribed Shares Note	107,628	107,628	107,628
Prepaid Expenses	4,992	4,992	4,992
Reserves and Surplus	0	0	0
<b>Total Other Assets</b>	<b>112,620</b>	<b>112,620</b>	<b>112,620</b>
<b>TOTAL ASSETS</b>	<b>167,839</b>	<b>167,839</b>	<b>163,981</b>



**SOHM, INC.**  
**QUARTERLY REPORT**  
**FOR THE QUARTER ENDED September 30, 2022**  
**BALANCE SHEET**  
**As of September 30, 2022**  
**(Unaudited)**

<b>PARTICULARS</b>	<b>QTR. 3<sup>rd</sup> – SEPT. 30, 2022</b>	<b>YEAR TO DATE 2022</b>	<b>As of Dec 31, 2021</b>
<b>LIABILITIES &amp; SHAREHOLDER'S EQUITY</b>			
<b>CURRENT LIABILITIES</b>			
Accounts Payables	149,210	149,210	127,152
Loan Payable and other current liabilities	1,565	1,565	1,324
Accrued Tax & Payroll liabilities	599	599	657
<b>Total Current Liabilities</b>	<b>151,374</b>	<b>151,374</b>	<b>129,133</b>
<b>LONG TERM NOTES PAYABLE</b>	996,152	996,152	1,074,560
<b>LOAN PAYABLE TO BANK &amp; OTHERS</b>	51,482	51,482	51,482
<b>TOTAL LIABILITIES</b>	<b>1,047,634</b>	<b>1,047,634</b>	<b>1,126,042</b>
<b>STOCKHOLDERS' EQUITY</b>			
Common Stock, authorized 2,000,000,000 shares of stock, 1,575,576,407 issued and outstanding at September 30, 2022 par value \$0.0001 per share and Preferred Stock authorized 100 share of stock and 51 issued and outstanding at September 30, 2022 par value \$0.0001 per share	3,798,426	3,798,426	3,798,426
Additional Paid in Capital	0	0	-
Subscribed Shares	445,504	445,504	445,504
Retained Earnings (Loss)	(1,476,673)	(1,476,673)	(1,536,698)
<b>Total Stockholders' Equity</b>	<b>(1,031,169)</b>	<b>(1,031,169)</b>	<b>(1,091,194)</b>
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<b>167,839</b>	<b>167,839</b>	<b>163,981</b>

**SOHM, INC.**  
**STATEMENT OF OPERATION**  
**FOR THE QTR ENDED**  
**SEPTEMBER 30, 2022 (Unaudited)**

<b>PARTICULARS</b>	<b>QTR. 3RD - SEPT.30, 2022</b>	<b>YEAR TO DATE 2022</b>	<b>As on Dec 31 2021</b>
<b>INCOME</b>			
Revenue	120,137	225,601	324,905
<b>Total Revenue</b>	<b>120,137</b>	<b>225,601</b>	<b>324,905</b>
<b>COST OF SALES</b>			
Cost of Goods Sold	57,666	87,119	151,294
Total Cost of Sales	57,666	87,119	151,294
<b>Gross Profit</b>	<b>62,471</b>	<b>138,482</b>	<b>173,611</b>
<b>EXPENSES</b>			
Sales and Marketing	8,121	10,929	23,091
General and Administrative	24,642	66,593	61,200
Research and Development	0	0	-
Depreciation Expense	0	0	0
Interest Expense	235	935	1,039
<b>Total Expense</b>	<b>32,999</b>	<b>78,458</b>	<b>85,330</b>
<b>Net Income before extraordinary Items</b>	<b>29,473</b>	<b>60,025</b>	<b>88,281</b>
Extraordinary Items		0	-
Loss before Provision for		0	-
Income Taxes		0	-
Provision for Income Taxes		0	-
<b>NET INCOME (LOSS)</b>	<b>29,473</b>	<b>60,025</b>	<b>88,281</b>
<b>Basic and Diluted Earnings</b>			
Earnings (Loss) per Common Share		0	-
<b>Basic and Diluted Weighted Average</b>			
Number of Common Shares	<b>1,575,576,407</b>	<b>1,575,576,407</b>	<b>1,575,576,407</b>

**SOHM, INC.**  
**STATEMENT OF CASH FLOWS**  
**as of September 30, 2022 (Unaudited)**

<b>PARTICULARS</b>	<b>QTR. 1ST - MARCH 31, 2020</b>	<b>QTR. 3RD - SEPT.30, 2022</b>	<b>YEAR TO DATE 2022</b>	<b>As on Dec 31 2021</b>
<b>Cash Flows from Operating Activities</b>				
Net Income (Loss)		29,473	60,025	88,281
Adjustment to Retained Earnings		0	0	-
Accounts Receivable		1,220	(1,990)	4,350
Inventory		(960)	(2,388)	(5,312)
Equipment		0	0	(10,620)
Loans and Advances		0	0	0
Accounts Payable		19,710	0	27,526
Current Liabilities-others		401	22,058	2,659
Accrued Payroll liabilities		0	183	(6,305)
Loans Payable		(50,264)	0	(98,983)
Depreciation Expense		0	(78,408)	0
Amortization Expense		0	0	0
Stock Issued for services		0	0	-
Stock Issued for special interest		0	0	-
Stock issued for capital		0	0	0
<b>Net Cash Provided by Operations</b>		<b>(420)</b>	<b>(520)</b>	<b>1,596</b>
<b>Cash Flows Used in Investing Activities</b>				
Fixed Asset Purchase (Sale)		0	0	0
Other Assets		0	0	0
<b>Net Cash Used for Investing</b>		<b>0</b>	<b>0</b>	<b>0</b>
<b>Cash Flows from Financing</b>				
Notes Payable		0	0	0
Sales of Stock		0	0	0
Capital Contributions		0	-	-
Subscribed Shares Note		0	0	0
Special Interest		0	-	-
<b>Cash Flows from Financing</b>		<b>0</b>	<b>0</b>	<b>0</b>
Net Increase (Decrease) in Cash		(420)	(520)	1,596
Cash, Beginning of Period		6,719	(520)	3,900
<b>Cash, End of Period</b>		<b>6,299</b>	<b>6,719</b>	<b>6,819</b>

**SOHM, INC.**  
**STATEMENT OF STOCKHOLDERS' EQUITY**  
**As of September 30, 2022**  
**(Unaudited)**

	Common Stock		Additional Paid in Capital	Stock Subscribed	Accumulated Deficit	Total Equity
	Shares	Amount				
Balance, December 31, 2006	114,310,000	104,310	1,217,440	150,000	(1,772,964)	(301,214)
Balance September 30, 2010	283,168,626	1,750,590	0	0	(1,896,462)	(145,872)
Balance December 31, 2010	329,107,088	2,059,946	0	0	(2,083,579)	(23,633)
Balance March 31, 2011	333,107,088	2,059,946	0	0	(2,244,598)	(184,652)
Balance June 20, 2011	368,323,806	2,359,946	0	0	(2,522,128)	(164,182)
Balance Sept 30, 2011	431,828,755	3,074,946	0	0	(2,580,349)	494,597
Balance December 31, 2011,	432,278,806	3,074,946	0	0	(2,632,569)	442,377
Balance December 31, 2012	496,063,353	3,249,196	0	0	(3,953,145)	(703,949)
Balance December 31, 2013	496,063,404	3,249,196	0	0	(4,977,426)	(703,949)
Balance March 31, 2014	534,230,020	534,230	0	0	(5,009,898)	(1,226,472)
Balance June 30, 2014	549,230,020	15,000	0	0		
Balance September 30, 2014	559,922,379					
Balance December 31, 2014	559,922,379					
Balance March 31, 2015	691,057,826					
Balance June 30, 2015	1,098,646,738	37,500	0	0		
Balance September 30, 2015	1,317,155,868	25,000	0	0		
Balance December 31, 2015	1,546,636,529	0	0	0		
Balance December 31, 2016	1,439,032,305	0	0	0		
Balance December 31, 2017	1,439,032,305	0	0	0		
Balance March 31, 2018	1,439,032,305	0	0	0		
Balance June 30, 2018	1,547,798,629					
Balance September 30, 2018	1,547,798,629	0	0	0		
Balance December 31, 2018	1,547,798,629	0	0	0		
Balance March 31, 2019	1,547,798,629	0	0	0		
Balance June 30, 2019	1,547,798,629	0	0	0		
Balance September 30, 2019	1,547,798,629	0	0	0		
Balance December 31, 2019	1,561,687,518	3725				
Balance March 31, 2020	1,561,687,518	0	0	0		
Balance June 30, 2020	1,575,576,407	3725				
Balance September 30, 2020	1,575,576,407	0	0	0		
Balance December 31, 2020	1,575,576,407	0	0	0		
Balance March 31, 2021	1,575,576,407	0	0	0		
Balance June 30, 2021	1,575,576,407	0	0	0		
Balance September 30, 2021	1,575,576,407	0	0	0		
Balance December 31, 2021	1,575,576,407	0	0	0		
Balance March 31, 2022	1,575,576,407	0	0	0		
Balance June 30, 2022	1,575,576,407	0	0	0		
Balance September 30, 2022	1,575,576,407	0	0	0		

## **SOHM, INC.**

### **NOTES TO FINANCIAL STATEMENTS September 30, 2022, and December 31, 2021**

#### **NOTE 1. OVERVIEW OF OPERATIONS AND ACCOUNTING POLICIES:**

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia.

The accompanying financial statements have been prepared to assume that the Company will continue as a going concern. As reflected in the accompanying financial statements, the Company had negative cash flow from operations and incurred a net loss during the previous few years. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to achieve sufficient cash flow from operations or secure adequate future financing and be therefore unable to continue as a going concern.

In the opinion of management, the accompanying balance sheets and related statements of income, cash flows, and stockholders' equity include all adjustments necessary for their fair presentation in conformity with U.S. generally accepted accounting principles. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results may differ from these estimates. The information included in this Form 211-75c should be read in conjunction with Management's Discussion and Analysis and financial statements and notes thereto included. Certain reclassifications have been made for consistent presentation.

#### **Revenue Recognition**

The Company generally recognizes revenue upon the accrual of interest earned on the tax lien certificates owned, as well as liquidating revenue from properties sold that the Company received through the settlement of unredeemed tax lien certificates.

#### **Deferred Revenue**

The deferred revenue shown in the balance sheet is the interest earned but not collected.

#### **Advertising, Sales & Marketing**

Advertising, sales & marketing costs are expensed as incurred. Advertising, sales & marketing expense totaled \$ 23,091 for the year ended December 31, 2021, and for the qtr. ended September 30, 2022, totaling \$ 8,121

The company implemented the new distribution of product policy, wherein super distributors have been replaced by CSA & CFA for effective and regulated sales.

#### **Inventory**

Inventory is stated at the lower of cost or net realizable value. The method used for inventory is first-in first out. Inventory consists of pharmaceutical products

## Property, Equipment, and Patents

Equipment is depreciated using the federal tax method over the estimated useful lives, which range from two to seven years.

## Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

## Earnings per Share

The basic earnings (loss) per share is calculated by dividing the Company's net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.

The Company has no potentially dilutive securities outstanding at the end of the statement periods. Therefore, the basic and diluted earnings (loss) per share are presented on the face of the statement of operations as the same number.

## Stock-Based Compensation

The Company accounts for its stock-based compensation based upon provisions in SFAS No. 123, Accounting for Stock-Based Compensation. In this statement stock-based compensation is divided into two general categories, based upon who the stock receiver is, namely, employees/directors and non-employees/directors. The employee's/director's category is further divided based upon the particular stock issuance plan, namely compensatory and non-compensatory. Each of these divisions treats the stock issuance for accounting purposes in a specific manner. The employee/director's non-compensatory securities are recorded when the stock is sold at the sales price. The compensatory stock may be recorded in one of two different methods. Compensation is calculated and recorded either at the securities' fair value or intrinsic value. The Company has selected to utilize the fair value method for valuing and recording options.

NOTE 2. NOTES PAYABLE AND CAPITAL LEASE OBLIGATIONS:

Notes payable and capital lease obligations consist of the following:

There are long-term notes payable and the long-term portion.

	For Year Ended	
	09/30/2022	12/31/2021
Total Long-Term Notes and short-term notes	996,152	1,074,560
Total Loan Payable to Bank & Others	51,482	51,482

NOTE 3. STOCKHOLDERS' EQUITY:

Authorized Capital Stock

The Company has total authorized capital of 2,000,000,100 shares consisting of 2,000,000,000 shares of common stock, \$.0001 par value per share, and 100 shares of preferred stock as of the date of the financial statements. Of the 2,000,000,100 shares authorized 1,575,576,407 common shares were issued and outstanding as of September 30, 2022, and 1,575,576,407 shares were issued and outstanding on December 31, 2021, and of the 100 Preferred Shares authorized 51 shares were issued and outstanding on December 31, 2021, and on September 30, 2022.

Stock-Based Compensation Paid for Services of Non-Employees

SFAS 123 provides that stock compensation paid to non-employees be recorded with a value that is based upon the fair value of the services rendered or the stock is given, whichever is more reliable. The common stock paid to non-employees was valued at the value of the stock issued. Below is a schedule that shows the common stock issued and the value of the services rendered for each of the periods.

Year Ended	Shares Issued	Value
December 31, 2020	13,888,889	\$ 3,725
December 31, 2021	0	\$ 0.00
September 30, 2022	0	\$ 0.00

NOTE 4. INCOME TAXES:

The Company provides for income taxes under Statement of Financial Accounting Standards No. 109, *Accounting for Income Taxes*. SFAS No. 109 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.

SFAS No. 109 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. In the Company's opinion, it is uncertain whether it will generate sufficient taxable income in the future to fully utilize the net deferred tax asset. Accordingly, a valuation allowance equal to the deferred tax asset has been recorded. The total deferred tax asset is \$450,300 which is calculated by multiplying the minimum federal corporate income tax rates by the respective NOL carryforwards, (15%). The total valuation allowance is a comparable \$ 450,300.

The total deferred tax asset is \$450,300 which is calculated by multiplying the minimum federal corporate income tax rates by the respective NOL carryforwards, (15%). The total valuation allowance is a comparable \$450,300.

The provision for income taxes is comprised of the net change in deferred taxes less the valuation account plus the current taxes payable as shown in the chart below.

	09/30/2022	12/31/2021
Net change in deferred taxes plus valuation	0	0
Current taxes payable	<u>0</u>	<u>0</u>
Provision for Income Taxes	<u>0</u>	<u>0</u>

Below is a chart showing the federal net operating losses and the years in which they will expire.

Year	Amount	Expiration
2004	0	2024
2005	136,737	2025
2006	173,910	2026
2007	185,000	2027
2008	-	-
2009	567,232	2029
2010	980,457	2030
2011	548,990	2031
2012	1,131,326	2032
2013	1,404,786	2033
<b>Total NOL</b>	<b>5,128,438</b>	

#### NOTE 5. LEASES AND OTHER COMMITMENTS:

The following is a listing of the operating leases that the Company had as of the period end and the monthly charges associated with those leases. The office lease is a renewable lease with the option to renew for the next two years starting on and ending each year, for which a new option agreement to be signed 90 days in advance of the expiration date, with a 5% increase or decrease based upon the fair market value determined by the increase or decrease in the prime rate. The office equipment is a fixed-cost lease with staggered expiration dates two years from the date of the agreement. The lease terms provide for a one-dollar buyout option at the end of the lease for which management intends on exercising, such as making the lease a capital lease. The Capital lease is depreciated over the useful life of years

	09/30/2022	12/31/2021
Office Equipment	4032.80	4032.80
Total Monthly	4032.80	4032.80

The monthly operating leases as of 09/30/2022 projected into the future for five years shows the following commitments:

	Year 1	Year 2	Year 3	Year 4	Year 5
Office Equipment	4032.80	4032.80	4032.80	4032.80	4032.80
Total Yearly Leases	4032.80	4032.80	4032.80	4032.80	4032.80



## NOTE 6: GOING CONCERN:

Listed below are some of the challenges that the Company is facing, and why these raise a question as to the Company's ability to continue as a going concern. Afterward, the explanation of the "going concern" problems, management plans to turn the Company around are described.

### Company's Challenges

The Company has survived with restructuring its operation and reducing its cost. The Company must continue to raise funds in the near future to survive as well as increase revenue and profitability. Management has been successful in the past in raising these funds. There is no assurance that management can continue to find investors to cover the losses generated.

The need to provide working capital adequacy is a major challenge. For sustainable expansions of manufacturing competencies, increased stringency of the regulatory framework, and need for expanded management bandwidth to capture opportunities through innovation. The capacities and soft skills reinforce each other in face of outstanding opportunities. One of the major hurdles that are faced today is when the large-scale chain of stores evaluates the products and innovation, it demands a scale of response. The capacity builds up require sustained adequacy on funds as well as focus and visions of business enterprise.

## NOTE 7. THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS:

Below is a listing of the most recent accounting standards SFAS 142-144 and their effect on the Company.

### SFAS 146      Accounting for Costs Associated with Exit or Disposal Activities

This statement requires companies to recognize costs associated with exit or disposal activities, other than SFAS 143 costs, when they are incurred rather than at the date of a commitment to an exit or disposal plan. Examples of these costs are lease termination costs, employee severance costs associated with restructuring, discontinued operation, plant closing, or other exit or disposal activity. This statement is effective after December 15, 2002.

### SFAS 147      Acquisitions of Certain Financial Institutions – an amendment of FASB Statement No. 72 and 144 and FASB Interpretation No. 9

This statement makes the acquisition of financial institutions come under statements 141 and 142 instead of statements 72, 144, and FASB Interpretation No. 9. This statement is applicable for acquisition on or after October 1, 2002.

### SFAS 148      Accounting for Stock-Based Compensation

This Statement amends FASB Statement No. 123, Accounting for Stock-Based Compensation, to provide alternative methods of transition for a voluntary change to the fair value-based method of accounting for stock-based employee compensation. In addition, this Statement amends the disclosure requirements of Statement 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results.

The adoption of these new Statements is not expected to have a material effect on the Company's financial position, results or operations, or cash flows.

#### NOTE 8. SEGMENT INFORMATION:

Segment information is presented in accordance with SFAS 131, Disclosures about Segments of an Enterprise and Related Information. This standard is based on a management approach, which requires segmentation based upon the Company's internal organization and disclosure of revenue based upon internal accounting methods.

#### NOTE 9. OTHER INFORMATION:

1. On January 19, 2016, Articles of Amendment were filed with the Nevada Secretary of State which decreased the authorized number of shares of Common Stock from 2 billion shares to 1 billion shares, par value \$0.0001 with no other changes to any other class of the Company's Capital Stock and decreased all issued and outstanding shares of Common Stock of the Corporation at the rate of one (1) share for every, one thousand (1,000) shares issued and outstanding. No action on the part of the shareholder or the Corporation is necessary, although, through its transfer agent, the shareholder may exchange existing certificates for new certificates representing the appropriate number of shares resulting from the decrease no other changes to any other class of the Company.
2. On February 10, 2016, a Corporate Action regarding January 16, 2016, Amendment was filed with FINRA.
3. On March 28, 2016, FINRA denied the February 10, 2016, Corporate Action.
4. On March 28, 2018, Articles of Amendment were filed with the Nevada Secretary of State Which increased the authorized number of shares of Common Stock from 1 billion shares to 2 billion shares and canceled the reverse split set forth on January 19, 2016, Articles of Amendment as filed.
5. On April 9, 2018, the company canceled one of its convertible notes which the company had since January 2014 and issued stocks to one of the financial investment companies as per the terms of notes. The company issued 108,766,324 stocks to them.
6. On December 6, 2019, the company has issued 13,888,889 restricted stocks to Stacey Jenkins Esq for the legal service rendered by him.
7. On June 10, 2020, the company issued 13,888,889 restricted stocks to Stacey Jenkins Esq for the legal service rendered by him.